BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Summary

An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.

Conditions

• Diabetes Mellitus, Type 2

Interventions

DRUG

DPP4

Dipeptidyl peptidase-4 inhibitors (DPP4) including alogliptin, linagliptin, sitagliptin, and saxagliptin

DRUG

GLP-1 receptor agonist

Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide

DRUG

Basal Insulin

degludec, detemir, glargine and NPH

DRUG

SLGT2

Sodium-glucose cotransporter-2 inhibitors (SLGT2) including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin

DRUG

SU

Sulfonylurea (SU) including glimepiride, glipizide, and glyburide

Sponsors & Collaborators

• Patient-Centered Outcomes Research Institute

  collaborator OTHER

• Baylor College of Medicine

  collaborator OTHER

• Baylor Scott and White Research Institute

  collaborator UNKNOWN

• The Cleveland Clinic

  collaborator OTHER

• HealthCore, Inc.

  collaborator INDUSTRY

• Humana Inc.

  collaborator INDUSTRY

• Massachusetts General Hospital

  collaborator OTHER

• Medical Outcomes Management

  collaborator UNKNOWN

• University of Iowa

  collaborator OTHER

• Allina Health

  collaborator UNKNOWN

• Intermountain Health Care, Inc.

  collaborator OTHER

• Marshfield Clinic

  collaborator UNKNOWN

• Medical College of Wisconsin

  collaborator OTHER

• University of Missouri-Columbia

  collaborator OTHER

• University of Utah

  collaborator OTHER

• Brigham and Women's Hospital

  lead OTHER

Principal Investigators

• Alexander Turchin, MD, MS · Brigham and Women's Hospital

Eligibility

Min Age

30 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-07-01

Primary Completion

2024-06-30

Completion

2024-06-30

FDA Drug

Yes

Countries

• United States

Study Locations